Methods of treating renal disease or treating at least one of muscle wasting, low muscle strength, or low physical function in a subject having renal disease by administering at least one tetrahydrocyclopenta[b]indole compound are disclosed. Also disclosed are methods of treating symptoms as a result of secondary hypogonadism induced by renal replacement therapy or kidney failure in a subject having renal disease by administering at least one tetrahydrocyclopenta[b]indole compound. The methods of treatment disclosed herein also include co-administration of the tetrahydrocyclopenta[b]indole compound with a second composition

Provided herein are nanoparticle compositions comprising a pharmaceutically acceptable carrier and a compound of Formula (II).

This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with an integrin inhibitor. In particular, the disclosure features the topical treatment of sections and subsections of the gastrointestinal tract by integrin inhibitors (like vedolizumab) using an ingestible device that can detect its whereabouts in the Gl tract by using reflectance and which is programmed to release the drugs at a given site or proximal thereto, to treat gastrointestinal inflammatory diseases. The device has hardware storage devices with instructions on board to determine the location and release the formulations. Combination therapies are claimed as well in which the integrin inhibitor is added systemically and another agent (e.g. JAK inhibitor, TNF-alpha inhibitor or IL-12/IL-23 inhibitor) is added topically by means of the ingestible device. The topical administration is said to reduce the side effects associated with systemic treatment.

There is disclosed herein a composition for treating gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers diarrhoea, chronic idiopathic nausea, IBD-associated constipation and diarrhoea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux esophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinson's disease, MS, Alzheimer's Disease, Motor Neuron Disease or autism, the composition comprising: (i) at least two anti-clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, aminoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (ii) at least one anti-clostridial agent selected from the above combined with an opioid blocking agent. There is also disclosed herein a method of treating various gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers diarrhoea, chronic idiopathic nausea, IBD-associated constipation and diarrhoea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux oesophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinson's disease, MS, Alzheimer's Disease, Motor Neuron Disease or autism, the method comprising administering orally, via enema or by suppository: (i) a composition of the invention; (ii) at least two anti-clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, aminoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (iii) at least one anti-clostridial agent selected from the above and an opioid blocking agent to a patient in need of such treatment.

Methods and compositions are provided herein for treating colorectal cancer in a subject, using one or more bacterial strains such as Bacteroides eggerthii 1 2 48FAA, Bacteroides eggerthii CCUG 9559, Bacteroides goldsteinii ATCC BAA 1180, Bacteroides pectinophilus N3, Bacteroides plebeius M12, Bacteroides vulgatus 8482, Barnesiella intestinihominis DSM 21032, Bifidobacterium stercoris EG1, Clostridium sp. 40, Clostridium spiroforme CCM 6168, Eubacterium eligens DSM 3376, Eubacterium hallii DSM 3353, Megamonas funiformis DSM 19343, Megasphaera elsdenii LC1, Parabacteroides johnsonii M-165, Butyricimonas virosa MT12, Clostridium citroniae DSM 19261, Lactobacillus ruminis RF3, Methanosphaera stadtmanae MCB-3, Ruminococcus sp. 18P13, Slackia piriformis DSM 22477, or Streptococcus hongkongensis HKU30.

Provided are anti-CD73 antibodies or fragments thereof. The antibodies or fragments therefore include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. More generally, antibodies or fragments thereof are described which have specificity to one or more amino acid residues selected from the C-terminal half of a human CD73 protein, such as those in the C-terminal domains. Specific epitope amino acids in these domains include Y345, D399, E400, R401 and R480. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer are also provided.

The present invention relates to novel peptides and a pharmaceutical compositions comprising the same. The peptide compounds and compositions disclosed herein are useful as therapeutic agents for treating eye diseases. When administered to the eyes, the peptide compounds and compositions disclosed herein increase the amount of tear secretion and promotes recovery of a damaged cornea.

This invention relates to pharmaceutically acceptable ergoline analogues and salts thereof. In particular, though not exclusively, the invention relates to formulations and uses of the same as a medicament.

Pharmaceutical compositions containing microbial entities are described herein. The pharmaceutical compositions may optionally contain or be used in conjunction with one or more prebiotics. Uses of the pharmaceutical compositions to treat or prevent disorders of the local or systemic microbiome in a subject are also provided.

The present invention relates to methods for treating chronic inflammatory conditions using a mast cell stabilizing compound. The invention further relates to compositions and dosage forms comprising mast cell stabilizing agents.